Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiaoyue Pill (also known as Xiaoying Wan) is a traditional Chinese medicine (TCM) oral herbal formulation developed and manufactured by Changchun Leiyunshang Pharmaceutical. It is an approved therapeutic in China, primarily indicated for the treatment of goiter (thyroid enlargement) and thyroid nodules. The formula is based on traditional principles of 'softening hardness and dissipating nodules,' a therapeutic approach used in TCM to address glandular swellings and masses in the neck area. The preparation typically contains a complex mixture of herbal ingredients, including iodine-rich seaweeds such as Sargassum (Haizao) and Laminaria (Kunbu), along with other components like Fritillaria (Beimu) that are traditionally used to resolve phlegm and reduce swellings. As a multi-herb TCM product, its clinical effect is attributed to the synergistic action of various phytochemicals rather than a single molecular target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xiaoyue Pill.